LXRX Q4 2017 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$693M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+43.5% YoY

Gross Profit

$33M98.4% margin

Operating Income

-$31M-93.2% margin

Net Income

-$28M-85.9% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+22.7%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$437M

Total Liabilities

$384M

Stockholders' Equity

$52M

Cash & Equivalents

$311M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$23M	+43.5%
Gross Profit	$33M	-$17M	+287.2%
Operating Income	-$31M	-$31M	+1.7%
Net Income	-$28M	-$32M	+12.5%